Manufacturers claim that gene patents, which now cover 25-40% of the human genome, are vital to recouping their investments. But such patents mar DNA’s “birthday” celebrations for the patients who stand to benefit from the fruits of genetic research – if only they could afford them.
制造商称，基因专利——目前覆盖了人类基因组的25—40%——是振兴投资的关键。但这些专利堪称DNA“生日”的污点，因为它们阻止了患者获得遗传研究的好处——除非他们花得起钱。